GF Value Analysis Flags Eli Lilly as 24.4% Undervalued as Oral GLP-1 Competition Accelerates in Obesity Market

The Quick Take

• GF Value proprietary analysis estimates Eli Lilly (LLY) is trading 24.4% below intrinsic value based on historical earnings and growth projections
• The obesity treatment sector is seeing accelerated competition from oral GLP-1 formulations gaining market traction faster than anticipated
• Lilly's tirzepatide franchise (Mounjaro, Zepbound) remains the dominant revenue driver but faces a crowded competitive pipeline by 2027

GF Value's analysis flagging Eli Lilly at 24.4% undervalued relative to its proprietary intrinsic value model is notable given LLY's position as one of the world's highest market capitalisation pharmaceutical companies. GF Value is a quantitative valuation framework from GuruFocus that blends historical price-to-earnings, price-to-book, and analyst earnings growth projections into a fair value estimate. For a company like LLY — which trades at significant premiums to sector peers due to its tirzepatide GLP-1 franchise dominance — a 24.4% undervaluation signal suggests that GF Value's model is assigning significant credit for sustained high-growth earnings through the mid-2030s, as tirzepatide generates peak sales potentially exceeding $30 billion annually.

The competitive acceleration in oral GLP-1 formulations is the key risk variable for this undervaluation thesis. As of mid-2026, Novo Nordisk, Roche, AstraZeneca, and Pfizer all have oral GLP-1 candidates in late-stage clinical development or early commercial launch. If any competitor successfully delivers an oral formulation with comparable efficacy to injectable tirzepatide at significantly lower cost, LLY's current market share and pricing power in the obesity segment would face compression. The GF Value analysis appears to model LLY maintaining dominant market share — a scenario that is plausible but not guaranteed given the pipeline competition.

The forward signal is the FDA approval decisions for competitor oral GLP-1 candidates over the next 12-18 months. A major competitor approval would trigger a re-rating of LLY's market share assumptions and potentially close the perceived undervaluation gap rapidly. Regulatory trigger is LLY's own Orforglipron (oral GLP-1) Phase 3 data, expected in late 2026, which will determine whether Lilly can defend its franchise from oral competition with its own oral product. The macro variable is US patient access and insurance coverage of GLP-1 drugs — any Medicare Medicaid policy changes dramatically alter the total addressable market calculations underlying LLY's valuation.

Synthesized from 1 source.